BG Medicine Announces Second Quarter 2011 Financial Results Release Date and Conference Call Information and Automatic Extension of IPO Lock-Up Agreements


WALTHAM, Mass., July 28, 2011 (GLOBE NEWSWIRE) -- BG Medicine Inc. (Nasdaq:BGMD) today announced that its financial results for the second quarter of fiscal year 2011 will be released prior to the market open on Thursday, August 11, 2011, followed the same day by a conference call and live webcast scheduled for 9:00am ET.

The conference call may be accessed by dialing 877-845-1016 from the U.S. and Canada, or 708-290-1155 from international locations. The conference call will also be available via the Internet at www.bg-medicine.com.

A replay of the call will be available approximately one hour following the end of the call through August 18, 2011. The replay may be accessed by dialing 855-859-2056 within the U.S. and Canada or 404-537-3406 from international locations, passcode 87109236. The call will be archived and accessible on the Web site for approximately 30 days.

Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.

In connection with the Company's scheduled earnings release and an announcement made by the Company yesterday and pursuant to FINRA rules and the Company's lock-up agreements between its pre-IPO stockholders and the IPO underwriters, the terms of the Company's post-IPO lock-up period has been automatically extended through August 31, 2011.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. BG Medicine also has products under development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8765



            

Contact Data